Vantrela ER FDA Approval History
FDA Approved: Yes (Discontinued) (First approved January 17, 2017)
Brand name: Vantrela ER
Generic name: hydrocodone bitartrate
Dosage form: Extended-Release Tablets
Company: Teva Pharmaceuticals USA, Inc.
Treatment for: Pain
Marketing Status: Discontinued
Vantrela ER (hydrocodone bitartrate) is an abuse deterrent opioid formulation for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment.
Development timeline for Vantrela ER
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.